Cancer J
-
Publication Venue For
- Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) Era.. 22:267-273. 2016
- Stereotactic Body Radiotherapy for Oligometastasis: Opportunities for Biology to Guide Clinical Management.. 22:247-256. 2016
- Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.. 21:322-326. 2015
- The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma.. 21:351-356. 2015
- Alternative fuels for cancer cells.. 21:49-55. 2015
- Common responses of tumors and wounds to hypoxia.. 21:75-87. 2015
- From the guest editor: an integrated multidisciplinary view of tumor metabolism.. 21:47-48. 2015
- Novel therapeutic targets of tumor metabolism.. 21:62-69. 2015
- Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer.. 19:200-207. 2013
- Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer.. 19:25-33. 2013
- Improvement in prostate cancer survival over time: a 20-year analysis: the Will Rogers phenomenon returns.. 18:9-10. 2012
- Electronic toxicity monitoring and patient-reported outcomes.. 17:231-234. 2011
- Adaptive radiation therapy: technical components and clinical applications.. 17:182-189. 2011
- Advances in treatment techniques: arc-based and other intensity modulated therapies.. 17:166-176. 2011
- Head and neck cancer as a model for advances in imaging prognosis, early assessment, and posttherapy evaluation.. 17:159-165. 2011
- Standards for palliative care delivery in oncology settings.. 16:436-443. 2010
- Combinations of Bevacizumab With Cancer Immunotherapy.. 24:193-204.
- Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.. 26:64-75.
- The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.. 26:376-381.